RegrowProtocol

Trial pipeline · NCT07518342

The Effect of Nanofat Injection on Androgenetic Alopecia

Phase 4 Not yet recruiting status last verified 2026-03

A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.

The registered record

Accession number
NCT07518342
Lead sponsor
Assiut University (other)
Registered conditions naming hair loss
Androgenetic AlopeciaAndrogenetic Alopecia (AGA)
Official title
Efficacy and Safety of Nanofat Injection vs Either PRP Injection or Topical Minoxidil 5% in Female and Male Pattern Androgenetic Alopecia

Interventions

  • DrugMinoxidil 5 %
  • ProcedurePRP injection
  • ProcedureNanofat injection

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type
interventional
Phase
Phase 4
Allocation
randomized
Masking
none
Primary purpose
treatment
Enrolment
60 participants (estimated)
Sites
1 location in Egypt

What it measures

  1. Clinical improvement by using trichoscopy and photographs

    Time frame: All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

  2. Trichoscopic improvement

    Time frame: All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

  3. patient satisfaction score

    Time frame: All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex
all
Age
18 Years to 50 Years
Healthy volunteers
not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start
April 2026 (estimated)
Primary completion
June 2028 (estimated)
Study completion
December 2028 (estimated)
First posted
8 April 2026 (actual)
Last update posted
13 April 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2028-06 is a month, and rendering it as 1 June 2028 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT07518342 on ClinicalTrials.gov · All 157 trials in the pipeline